OPEN END TURBO OPTIONSSCHEIN LONG - BECTON DICKINSON AND CO. Share Price

Certificat

DE000GZ0KZQ4

Real-time BOERSE MUENCHEN 09:56:00 20/06/2024 pm IST
2.04 EUR +17.92% Intraday chart for OPEN END TURBO OPTIONSSCHEIN LONG - BECTON DICKINSON AND CO.
Current month+16.11%
1 month-16.02%
Date Price Change
20/24/20 2.04 +17.92%
19/24/19 1.73 -0.57%
18/24/18 1.74 -0.57%
17/24/17 1.75 -1.13%
14/24/14 1.77 +6.63%

Real-time BOERSE MUENCHEN

Last update June 20, 2024 at 09:56 pm IST

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Goldman Sachs
WKN GZ0KZQ
ISINDE000GZ0KZQ4
Date issued 23/09/2022
Strike 214.8 $
Maturity Unlimited
Parity 10 : 1
Emission price 4.86
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 7.78
Lowest since issue 0.88
Spread 0.02
Spread %0.99%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
233.7 USD
Average target price
279.2 USD
Spread / Average Target
+19.45%
Consensus